Loading...
•
Sep 30, 2025
Fulgent Q3 2025 Earnings Report
Fulgent posted year-over-year revenue growth and achieved positive non-GAAP income in Q3 2025 despite a GAAP net loss.
Key Takeaways
Fulgent reported 17% year-over-year revenue growth in Q3 2025, with GAAP losses narrowing and non-GAAP profitability achieved through margin expansion and cost controls.
Revenue grew to $84.1 million, a 17% increase year-over-year.
GAAP net loss narrowed to $6.6 million, or $(0.21) per share.
Non-GAAP income reached $4.5 million, or $0.14 per share.
GAAP gross margin was 42.2%, while non-GAAP gross margin was 44.3%.
Revenue by Segment
Forward Guidance
Fulgent raised its full-year 2025 revenue and EPS outlook, signaling confidence in ongoing momentum and execution.
Positive Outlook
- Raised full-year 2025 revenue guidance to $325 million.
- Increased full-year 2025 non-GAAP EPS guidance to $0.30.
- Maintained strong balance sheet with nearly $800 million in cash and investments projected by year-end.
- Progress on key therapeutic programs including FID-007 and FID-022.
- Operating leverage expected to improve in Q4.
Challenges Ahead
- Full-year GAAP EPS remains in loss territory at approximately ($1.70).
- Cash flow impacted by R&D and strategic investments.
- Equity-based compensation remains a significant expense driver.
- Margin improvements could be pressured by development costs.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...